ArticleKidney medicine2022

Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States.

Julie Z Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.